Roux-en-Y gastric bypass surgery is effective in fibroblast growth factor-21 deficient mice.
OBJECTIVE
The mechanisms by which bariatric surgeries so effectively and lastingly reduce body weight and normalize metabolic dysfunction are not well understood. Fibroblast growth fator-21 (FGF21) is a key regulator of metabolism and is currently considered for treatment of obesity. Although elevated by acute food deprivation, it is downregulated after weight loss induced by chronic calorie restriction but not after Roux-en-Y gastric bypass surgery. Therefore, the goal of the present study was to assess the role of FGF21-signaling in the beneficial effects of Roux-en-Y gastric bypass surgery (RYGB).


METHODS
High-fat diet-induced obese FGF21-deficient (FGF21(-/-)) and wildtype (WT) mice were subjected to RYGB, sham surgery, or caloric restriction to match body weight of RYGB mice. Body weight, body composition, food intake, energy expenditure, glucose tolerance, and insulin sensitivity, as well as plasma levels and hepatic mRNA expression of FGF21 were measured.


RESULTS
Hepatic expression and plasma levels of FGF21 are higher after RYGB compared with similar weight loss induced by caloric restriction, suggesting that elevated FGF21 might play a role in preventing increased hunger and weight regain after RYGB. However, although the body weight differential between RYGB and sham surgery was significantly reduced in FGF21(-/-) mice, RYGB induced similarly sustained body weight and fat mass loss, initial reduction of food intake, increased energy expenditure, and improvements in glycemic control in FGF21(-/-) and WT mice.


CONCLUSIONS
FGF21 signaling is not a critical single factor for the beneficial metabolic effects of RYGB. This may open up the possibility to use FGF21 as adjuvant therapy in patients with ineffective bariatric surgeries.
Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.
Christopher D
CD
Morrison
Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.
Zheng
Z
Hao
Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.
Michael B
MB
Mumphrey
Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.
R Leigh
RL
Townsend
Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.
Heike
H
Münzberg
Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.
Jianping
J
Ye
Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA. Electronic address: berthohr@pbrc.edu.
Hans-Rudolf
HR
Berthoud
Body weight; Diabetes; Energy expenditure; Food intake; Glucose tolerance; Insulin; Leptin; Obesity
Diabetes. 2010 Jul;59(7):1817-24
20357365
Endocrinology. 2015 Jun;156(6):2087-102
25774553
Obes Surg. 2016 Sep;26(9):2173-82
26781597
Am J Physiol Regul Integr Comp Physiol. 2014 Mar 1;306(5):R352-62
24430883
Diabetes Obes Metab. 2015 Jun;17(6):566-72
25732625
Diabetes Care. 2009 Aug;32(8):1542-6
19487637
N Engl J Med. 2014 May 22;370(21):2002-13
24679060
Diabetes Care. 2010 Jul;33(7):1438-42
20368410
Diabetes. 2008 May;57(5):1246-53
18252893
Am J Physiol Regul Integr Comp Physiol. 2011 Sep;301(3):R581-600
21677272
Cell Metab. 2013 Sep 3;18(3):333-40
24011069
Cell Metab. 2015 May 5;21(5):731-8
25955208
Gastroenterology. 2010 Aug;139(2):456-63
20451522
Clin Endocrinol (Oxf). 2014 Dec;81(6):862-70
24841294
Int J Obes (Lond). 2016 Feb;40(2):281-90
26303352
Obes Surg. 2014 Nov;24(11):1835-42
25027982
Cell Metab. 2007 Jun;5(6):426-37
17550778
Ann Surg. 2006 Jan;243(1):108-14
16371744
Endocrinology. 2015 Jul;156(7):2470-81
25924103
Cell Metab. 2013 Sep 3;18(3):307-9
24011067
Nat Med. 2015 Jan;21(1):27-36
25485909
Cell Metab. 2016 Feb 9;23 (2):344-9
26724861
Int J Obes (Lond). 2012 Mar;36(3):348-55
22124454
Diabetes. 2009 Jan;58(1):250-9
18840786
Endocrinology. 2010 Apr;151(4):1588-97
20179262
Sci Transl Med. 2013 Mar 27;5(178):178ra41
23536013
Mol Metab. 2013 Dec 11;3(2):191-201
24634822
Am J Physiol Regul Integr Comp Physiol. 2009 Nov;297(5):R1273-82
19726714
Endocrinology. 2008 Dec;149(12):6018-27
18687777
PLoS One. 2014 Nov 26;9(11):e112109
25427253
Clin Endocrinol (Oxf). 2014 Jun;80(6):834-42
23711328
Obesity (Silver Spring). 2016 Mar;24(3):654-60
26847390
J Clin Invest. 2014 Sep;124(9):3913-22
25133427
Metab Brain Dis. 2016 Apr;31(2):239-48
26738728
Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10853-8
19541642
Cell Metab. 2016 Feb 9;23 (2):335-43
26724858
Diabetes. 2013 Sep;62(9):3027-32
23610060
Trends Endocrinol Metab. 2014 Jun;25(6):303-11
24709036
Cell Rep. 2016 Jul 19;16(3):707-16
27396336
Cell Metab. 2016 Mar 8;23 (3):427-40
26959184
Endocrinology. 2012 May;153(5):2234-44
22416083
J Clin Invest. 2005 Jun;115(6):1627-35
15902306
Cell Metab. 2007 Jun;5(6):415-25
17550777
Diabetes. 2013 Jul;62(7):2380-5
23434938
Int J Obes (Lond). 2011 Sep;35 Suppl 3:S40-4
21912387
Dig Dis. 2011;29(1):48-51
21691104
Clin Nutr. 2016 May 4;:null
27188262
Surg Endosc. 2011 Apr;25(4):1176-81
20844896
J Endocrinol. 2015 Oct;227(1):37-47
26294388